Company intelligence / Profile preview

Chengdu Silara Meditech

Ownership: Private
Development stage: Other

Overview

Chengdu Silara Meditech is developing transcatheter heart valve systems, including both aortic and mitral solutions. Their transcatheter aortic valve system is undergoing prospective, multi-center clinical trials to evaluate safety and effectiveness in patients with severe aortic stenosis. The company has also developed the "Silara MiBridge™" system for mitral valve repair, which has completed its first-in-human procedure as of June 2023.

Therapeutic areas: Cardiovascular
Modalities: DeviceBiologic
Industry: Implantable Medical Devices

Beyond the preview

Go deeper on Chengdu Silara Meditech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Silara Meditech.

Explore the full profile